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Aims: We aimed to evaluate six months of results following repeated GON blocks.
Methods: We evaluated the results from GON block performed on 60 patients. Brieﬂy,
we applied a standard 2 mL of 0.5% Bupivacaine GON blockage once a week for 4 weeks.
We recorded the Visual Analog Scale (VAS) scores, the number of migraine attacks and the
Migraine Disability Assessment Questionnaire (MIDAS) scores. The study subjects were not
allowed to use medication for prophylaxis, and Ibuprofen (400 mg, 1200 mg at maximum)
was prescribed for any migraine attacks.
Results: The initial mean number of attacks per month before starting treatment was 8.33
+ 2.31. After treatment, the initial MIDAS mean was found to be 2.82 per month; this declined
to 1.47 in 3rd, and was 1.50 in the 6th month. The individual month values were found to be
signiﬁcant, and were listed respectively as, 1st month: 3.95 + 2.52, 2nd month: 3.23 + 1.82, 3rd
month: 2.60 + 1.90, 4th month: 2.68 + 2.10, 5th month: 2.58 + 1.90 and 6th month: 2.58 + 1.90.
The mean VAS scores were recorded as follows for each month: 6.28  1.24, 3.13  0.97, 2.55
 1.19, 2.35  1.26, 2.38  1.20 and 2.48  1.30, respectively. This difference was noted to be
statistically signiﬁcant. No difference regarding the efﬁcacy of the treatment was deter-
mined when the results were compared across age groups.
Conclusion: We assume that GON blockage with 2 mL of 0.5% Bupivacaine can be a supportive
treatment in migraine treatment, with no serious adverse effects reported.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Migraine is a chronic disease which is characterized by recurrent
mild or severe headaches, mostly related to a group of signs that* Corresponding author at: Department of Neurosurgery, Abant Izzet B
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E-mail address: dagistanyasar@hotmail.com (Y. Dagistan).
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0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Soriginate in the autonomic nervous system. The prominent
theory regarding migraine, which is thought to be of neurovas-
cular origin, is that it is triggered by an excitation of the cerebral
cortex with abnormal control of the pain-related neurons in the
trigeminal nucleus which are located in the brain stem.aysal University School of Medicine, 14280 Gölköy, Bolu, Turkey.
p. z o.o. All rights reserved.
Table 1 – Age groups of the subjects.
Age groups n %
≤34 years 13 21.67
35–39 years 16 26.67
40–44 years 13 21.67
≥45 years 18 30.00
Table 2 – Comparison of the MIDAS scores.
MIDAS Mean SS p Difference
Prior to
procedurea
2.82 0.70 0.000
(F = 178.45)
a and b, c
3rd monthb 1.47 0.72 b and a
6th monthc 1.50 0.68 c and a
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primary ramus of the C2 segmental nerve and, to a lesser
extent, the C3 cervical nerve [1]. Administration of a nerve
block into the greater occipital nerve (GON) results in a
blocking of the impulses from the site to areas innervated by
it. In this way the load of input on the convergent neurons of
the 2nd cervical neuron's dorsal horn is diminished and
their sensitization is obstructed [2]. It is noted in the
literature that the upper cervical nerves and the nucleus of
the trigeminal nerve are connected [3]. Also, it has been
shown that GON blocks and electrical stimuli to the cervical
muscles increase the responses in the second cervical
nerve's convergent neurons [4]. There is not yet a complete
classiﬁcation, but differences are evident in the results of
GON blocks in patients with a diagnosis of cervicogenic,
cluster and migraine headaches [5–7]. The outcomes of trials
where blocks have been applied more than once are
promising [8,9]. In trials with neurostimulation, the out-
comes from recurrent or continuous stimulation verify the
augmented efﬁcacy of a GON block being applied more than
once [10,11].
In this study, we aimed to evaluate six months of results
following repeated GON blocks.
2. Materials and methods
60 patients, who were diagnosed with migraine, according to
the International Headache Society (IHS) criteria (IHS, 2004),
were included in a 6-month cohort study, after gathering
each patient's written consent and the conﬁrmation of the
ethical committee [12]. Patients who were pregnant or
nursing at the time of the trial, or who had experienced a
previous surgical procedure at the site of the injection were
excluded. When the patient was in a sitting position, with the
head in hyperﬂexion, 2 mL of 0.5% Bupivacaine injection was
applied medially and laterally to the occipital nerve with a
5 cm of 22 gauge needle after palpating the artery in the
region which is on the 1/3 part, close to the occipital
protuberance and on an imaginary line that is drawn from
the occipital protuberance to the mastoid. This was admin-
istered following an appropriate site cleansing with povio-
dine iodochloride. Patients were under observation for
30 min after the injection, and no medical device was used.
Any complications in the subjects, for which the block level
was evaluated by a pinprick test, were recorded. Blocks were
repeated once a week for a month. No medical prophylaxis
was given to the patients during the observational period of 6
months. For treatment of acute migraine attacks, Ibuprofen
(400 mg, 1200 mg at maximum) was prescribed. During six
month period, the number of attacks, the VAS level during
the attack (VAS, is a horizontally or vertically drawn line,
10 cm in length, on which at one end ‘‘no pain’’ and at the
other end ‘‘severe pain’’ is written), and a calculation of
MIDAS (The Migraine Disability Assessment Questionnaire)
scores on 3rd and 6th months were collected. MIDAS has
been tested by Lipton et al. regarding its validity, ease of use,
conﬁdence, and its signiﬁcance to health workers [13]. Ertas
et al. validated the test (2004), and Gedikoglu et al. updated
the test in 2005 [14,15].3. Analysis of the data
SPSS 21.0 statistics packaged software was utilized for the
analysis of the data. In the analysis, descriptive statistical
methods (frequency, percentage, mean, standard deviation,
respectively), One Way Anova and Repeated Measures Anova
were used. In multiple comparisons where there was a
difference between groups, Dunnet and Tukey HSD tests were
chosen for discrimination purposes. Values with a probability
of p < 0.05 were accepted as signiﬁcant, whereas bigger values
were identiﬁed as non-signiﬁcant and no differences between
the groups were reported.
4. Results
60 patients with a diagnosis of migraine were included, and
when the subjects were evaluated in relation to age groups no
signiﬁcance was seen (p > 0.05) (Table 1). When the MIDAS
scores were compared, there was a signiﬁcant difference
between them: the mean MIDAS score prior to the procedure
was found to be 2.82, whereas this value declined to 1.47 in the
3rd month and was 1.50 in the 6th month ( p < 0.05) (Table 2). In
a comparison of VAS scores, the initial mean value for VAS was
6.28; the VAS scores during the following 6 months of
observation were lower, and the difference was found to be
signiﬁcant (p < 0.05) (Table 3). The initial value for the number
of attacks was 8.33, however, when compared to the values in
the six months of follow-up, it was found to be lower, which
was also signiﬁcant (p < 0.05) (Table 4). In each period of
measurement there was no signiﬁcant difference in a
comparison according to the age groups regarding MIDAS,
VAS or the number of attacks (p > 0.05) (Table 5).
5. Discussion
Invasive procedures aimed at the peripheral nerves are
becoming more popular nowadays; but, still, there are no
completely accepted protocols for these procedures. Trials
Table 3 – Comparison of the VAS scores.
VAS Mean SS p Difference
Prior to procedurea 6.28 1.24 0.000
(F = 166.52)
a and b, c, d, e, f, g
1st measurementb 3.13 0.97 b and a, c, d, e, f, g
2nd measurementc 2.55 1.19 c and a, b
3rd measurementd 2.42 1.23 d and a, b
4th measuremente 2.35 1.26 e and a, b
5th measurementf 2.38 1.20 f and a, b
6th measurementg 2.48 1.30 g and a, b
Table 4 – Comparison between number of attacks.
Number of
attacks
Mean SS p Difference
Prior to procedurea 8.33 2.31 0.000
(F = 82.05)
a and b, c, d, e, f, g
1st measurementb 3.95 2.52 b and a, d, e, f, g
2nd measurementc 3.23 1.82 c and a
3rd measurementd 2.60 1.90 d and a, b
4th measuremente 2.68 2.10 e and a, b
5th measurementf 2.58 1.90 f and a, b
6th measurementg 2.58 1.90 g and a, b
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results. Even though these conﬂicting results conﬁrm the need
for more studies in this ﬁeld, the GON block is widely accepted
to be effective in controlling headaches [16,17].
Another point still under discussion is the choice of
medication to be used in the procedure. The current approach
is to use local anesthetics and local anesthetic-steroid
mixtures. Aﬁrdi et al. [18] applied GON block with 3 mL of
2% lidocaine and 80 mg of prednisolone, and results were
recorded 1 week prior to and 4 weeks after the procedure.
The number of patients with a complete response was 26/101;
36/101 showed a partial response, in which the severity and
frequency of the attacks were reduced by 30%; 54 of the 101
patients were included in the diagnosis of migraine. Complete
response in these patients lasted for 9 days; in addition, a
partial response lasted for 61 days on average. In the latter
period of the trial there was no signiﬁcant correlation between
the immediate efﬁcacy of the block after the injection and the
longer term probability of success. Regarding complications
with GON block, 2 patients had alopecia, one had vasovagal
syncope, 3 patients had dizziness, and 3 had atypical pain. In
our study, we observed complications in 5 of our subjects: 3Table 5 – MIDAS, VAS and number of attacks comparison acco
<34 years (n = 13) 35–39 years (n = 16) 
Mean  SD Mean  SD 
MIDAS
Prior to procedure 3.00  0.82 2.69  0.79 
3rd month 1.31  0.48 1.56  0.81 
6th month 1.54  0.66 1.50  0.82 
VAS
Prior to procedure 6.62  1.19 6.38  1.02 
1st measurement 3.15  1.07 3.00  0.89 
2nd measurement 2.92  1.32 2.13  0.89 
3rd measurement 2.46  1.33 2.19  0.98 
4th measurement 2.38  1.50 2.25  0.93 
5th measurement 2.54  1.20 2.13  0.89 
6th measurement 2.54  1.61 2.13  1.20 
Number of attacks
Prior to procedure 7.77  2.42 9.25  2.67 
1st measurement 2.92  2.87 3.63  1.75 
2nd measurement 2.38  1.33 3.38  1.45 
3rd measurement 2.46  1.56 2.75  2.65 
4th measurement 2.46  1.39 2.75  2.74 
5th measurement 2.46  1.56 2.75  2.65 
6th measurement 2.46  1.56 2.75  2.65 
NS: non-signiﬁcant.had vasovagal syncope and 2 patients had atypical pain
(a headache which spread to the neck).
Ashkenazi et al. applied GON block (2 cc of 2% lidocaine
+ 5 mg of triamcinolone) and a triggering point injection (0.5 cc
of 2% lidocaine) to 15 of 19 patients; the GON block alone was
applied to the other 4 patients [19]. The pain scores in all
groups were reduced from 6.53 to 3.47, and they reported the
GON block to have had a positive outcome in headache
management. Additionally, Lauretti et al. used three different
volumes of 10 mg dexamethasone + 40 mg of lidocaine, deliv-
ered as 5, 10 and 15 mL, and reported that the dose of 5 mL was
sufﬁcient to create a sub-compartmental block [20]. In our
study, we applied a GON block with 2 mL of Bupivacaine. Even
though we practiced a different technique, we documented a
decline in the VAS scores, from an initial mean value of 6.28 to
a mean value of 2.48 in the 6th month. Moreover, we recorded
signiﬁcantly decreasing values in the MIDAS scores and in the
number of attacks in the 6-month period. Our rate of success
was similar to that of studies described in the literature
[8,9,18,19]. We assume that our high rate of success was related
to the administration of nerve blocks more than once, and tording to the age groups.
40–44 Years (n = 13) 45 and older (n = 18) p
Mean  SD Mean  SD
2.92  0.49 2.72  0.67 NS
1.54  0.88 1.44  0.70 NS
1.46  0.66 1.50  0.62 NS
5.69  1.11 6.39  1.46 NS
3.31  1.03 3.11  0.96 NS
2.77  1.48 2.50  1.04 NS
2.69  1.49 2.39  1.20 NS
2.77  1.42 2.11  1.23 NS
2.77  1.48 2.22  1.22 NS
2.69  1.32 2.61  1.14 NS
9.08  1.26 7.39  2.15 0.050
5.08  2.63 4.17  2.60 NS
3.92  1.98 3.22  2.16 NS
2.38  0.87 2.72  1.99 NS
2.69  2.39 2.78  1.80 NS
2.31  0.85 2.72  1.99 NS
2.31  0.85 2.72  1.99 NS
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anesthetic through both sides of the occipital nerve, laterally
and medially to the nerve, during the GON block. We have
realized that in the literature the administration was per-
formed only to the medial side of the nerve with the lateral
part being ignored [21].
In recent years, neurostimulators have been used in
preference to GON for migraine. The results of those trials
are promising, even though they have only been carried out
with small numbers of patients. In a study with a group of 25
patients, neurostimulation of the occipital nerve had a success
rate of 50% [10]. Additionally, Oh et al. stated that a 90.2% relief
in 6 out of 20 patients and a 75–90% relief in another 2 patients
by the end of 6 months [11]. Thus, a continuous stimulator,
such as in recurrent occipital nerve stimulation, will increase
the probability of success.
In conclusion, the GON block is not a successful method
for achieving a complete cure in migraine type headaches
but that it can be a supportive option in treatment. Because
there were no signiﬁcant differences in the efﬁcacy of the
treatment between age groups and there is the potential for a
wide-range of application in patient populations diagnosed
with migraine.
Conﬂict of interest
None declared.
Acknowledgement and ﬁnancial support
None declared.
Ethics
The work described in this article has been carried out in
accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involv-
ing humans; Uniform Requirements for manuscripts submit-
ted to Biomedical journals.
r e f e r e n c e s
[1] Bogduk N, Govind J. Cervicogenic headache: an assessment
of the evidence on clinical diagnosis, invasive tests, and
treatment. Lancet Neurol 2009;8:959–68.
[2] Selekler MH. [Greater occipital nerve blockade:
trigeminicervical system and clinical applications in
primary headaches]. Agri 2008;20:6–13.
[3] Piovesan EJ, Kowacs PA, Tatsui CE, Lange MC, Ribas LC,
Werneck LC. Referred pain after painful stimulation of the
greater occipital nerve in humans: evidence of convergenceof cervical afferences on trigeminal nuclei. Cephalalgia Int J
Headache 2001;21:107–9.
[4] Bartsch T, Goadsby PJ. Increased responses in
trigeminocervical nociceptive neurons to cervical input
after stimulation of the dura mater. Brain J Neurol
2003;126:1801–13.
[5] Bovim G, Sand T. Cervicogenic headache, migraine without
aura and tension-type headache. Diagnostic blockade of
greater occipital and supra-orbital nerves. Pain 1992;51:43–8.
[6] Peres MF, Stiles MA, Siow HC, Rozen TD, Young WB,
Silberstein SD. Greater occipital nerve blockade for cluster
headache. Cephalalgia Int J Headache 2002;22:520–2.
[7] Naja ZM, El-Rajab M, Al-Tannir MA, Ziade FM, Tawﬁk OM.
Repetitive occipital nerve blockade for cervicogenic
headache: expanded case report of 47 adults. Pain Pract Off J
World Inst Pain 2006;6:278–84.
[8] Takmaz SA, Inan N, Ucler S, Yazar MA, Inan L, Basar H.
Greater occipital nevre block in migraine headache:
preliminary results of 10 patients. Agri 2008;20:47–50.
[9] Caputi CA, Firetto V. Therapeutic blockade of greater
occipital and supraorbital nerves in migraine patients.
Headache 1997;37:174–9.
[10] Popeney CA, Alo KM. Peripheral neurostimulation for the
treatment of chronic, disabling transformed migraine.
Headache 2003;43:369–75.
[11] Oh MY, Ortega J, Bellotte JB, Whiting DM, Alo K. Peripheral
nerve stimulation for the treatment of occipital neuralgia
and transformed migraine using a c1-2-3 subcutaneous
paddle style electrode: a technical report. Neuromodul J Int
Neuromodul Soc 2004;7:103–12.
[12] Gladstone JP, Dodick DW. Revised 2004 International
Classiﬁcation of Headache Disorders: new headache types.
Can J Neurol Sci 2004;31:304–14.
[13] Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M.
Prevalence and burden of migraine in the United States:
data from the American Migraine Study II. Headache
2001;41:646–57.
[14] Ertas M, Siva A, Dalkara T, Uzuner N, Dora B, Inan L, et al.
Validity and reliability of the Turkish Migraine Disability
Assessment (MIDAS) questionnaire. Headache 2004;44:
786–93.
[15] Gedikoglu U, Coskun O, Inan LE, Ucler S, Tunc T, Emre U.
Validity and reliability of Turkish translation of Migraine
Disability Assessment (MIDAS) questionnaire in patients
with migraine. Cephalalgia Int J Headache 2005;25:452–6.
[16] Ashkenazi A, Blumenfeld A, Napchan U, Narouze S,
Grosberg B, Nett R, et al. Peripheral nerve blocks and trigger
point injections in headache management – a systematic
review and suggestions for future research. Headache
2010;50:943–52.
[17] Levin M. Nerve blocks in the treatment of headache.
Neurother J Am Soc Exp NeuroTherapeutics 2010;7:197–203.
[18] Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital
nerve injection in primary headache syndromes – prolonged
effects from a single injection. Pain 2006;122:126–9.
[19] Ashkenazi A, Young WB. The effects of greater occipital
nerve block and trigger point injection on brush allodynia
and pain in migraine. Headache 2005;45:350–4.
[20] Lauretti GR, Correa SW, Mattos AL. Efﬁcacy of the greater
occipital nerve block for cervicogenic headache: comparing
classical and subcompartmental techniques. Pain Pract Off
J World Inst Pain 2014.
[21] S. E. Algolojide Girişimsel İşlemler Nobel tıp kitabevi2012.
